A multicenter phase III randomized study on 168 patients with unresectable stage IIIC-IV melanoma was conducted to compare the efficacy of ACT with TIL vs. ipilimumab, with the majority of patients being refractory to anti-PD1 therapy. This evidence concerns the gene PDCD1 and melanoma.